{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:32:30Z","timestamp":1787020350246,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Guangdong Province","award":["2025A1515012519"],"award-info":[{"award-number":["2025A1515012519"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82293634"],"award-info":[{"award-number":["82293634"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270178"],"award-info":[{"award-number":["82270178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Southern Medical University Key Program of Clinical Research Special Fund","award":["LC2024NF009"],"award-info":[{"award-number":["LC2024NF009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02994-x","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:05:01Z","timestamp":1781168701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activation of c-Myc confers resistance to venetoclax via inhibition of Bim in t(8;21)-positive acute myeloid leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DanDan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohong","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2994_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"2994_CR2","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Johnson I, McCullough K, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia. Haematologica. 2022;107:2501\u20135.","journal-title":"Haematologica"},{"key":"2994_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/joim.13581","volume":"293","author":"G Weng","year":"2023","unstructured":"Weng G, Zhang Y, Yu G, et al. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. J Intern Med. 2023;293:329\u201339.","journal-title":"J Intern Med"},{"key":"2994_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller A, Bazinet A, DiNardo CD, et al. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024;8:927\u201335.","journal-title":"Blood Adv"},{"key":"2994_CR5","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood.2023020649","volume":"142","author":"J Senapati","year":"2023","unstructured":"Senapati J, Urrutia S, Loghavi S, et al. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023;142:1647\u201357.","journal-title":"Blood"},{"key":"2994_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"},{"key":"2994_CR7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41375-024-02501-6","volume":"39","author":"R Shahswar","year":"2025","unstructured":"Shahswar R, Gabdoulline R, Krueger K, et al. A novel prognostic risk model for patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia. 2025;39:614\u201322.","journal-title":"Leukemia"},{"key":"2994_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3324\/haematol.2021.280201","volume":"107","author":"I Ferrarini","year":"2022","unstructured":"Ferrarini I, Rigo A, Visco C. The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine. Haematologica. 2022;107:790\u2013802.","journal-title":"Haematologica"},{"key":"2994_CR9","doi-asserted-by":"publisher","first-page":"eabo6891","DOI":"10.1126\/scitranslmed.abo6891","volume":"14","author":"GP Sullivan","year":"2022","unstructured":"Sullivan GP, Flanagan L, Rodrigues DA, T NC. The path to venetoclax resistance is paved with mutations, metabolism, and more. Sci Transl Med. 2022;14:eabo6891.","journal-title":"Sci Transl Med"},{"key":"2994_CR10","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1:1176\u201387.","journal-title":"Nat Cancer"},{"key":"2994_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2994_CR12","first-page":"501","volume":"44","author":"RH Mi","year":"2023","unstructured":"Mi RH, Chen L, Wang L, Ai H, Yin QS, Wei XD. Retrospective analysis of the efficacy and safety of Venetoclax-based regimen in the treatment of 12 cases of acute myeloid leukemia with t (8; 21). Zhonghua Xue Ye Xue Za Zhi. 2023;44:501\u20134.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2994_CR13","first-page":"134","volume":"43","author":"WJ Yu","year":"2022","unstructured":"Yu WJ, Jia JS, Wang J, et al. Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience. Zhonghua Xue Ye Xue Za Zhi. 2022;43:134\u201340.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2994_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41408-023-00928-1","volume":"13","author":"K Zhang","year":"2023","unstructured":"Zhang K, Zhang X, Xu Y, et al. Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia. Blood Cancer J. 2023;13:155.","journal-title":"Blood Cancer J"},{"key":"2994_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00432-024-05861-9","volume":"150","author":"Z Yin","year":"2024","unstructured":"Yin Z, Yao Z, Chen D, et al. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia. J Cancer Res Clin Oncol. 2024;150:336.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2994_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S, et al. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed\/Refractory AML: A Multicenter, Phase 2 Trial. J Hematol Oncol. 2023;16:42.","journal-title":"J Hematol Oncol"},{"key":"2994_CR17","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1182\/blood-2009-09-242545","volume":"117","author":"B Steffen","year":"2011","unstructured":"Steffen B, Knop M, Bergholz U, et al. AML1\/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. Blood. 2011;117:4328\u201337.","journal-title":"Blood"},{"key":"2994_CR18","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1128\/MCB.24.7.2890-2904.2004","volume":"24","author":"C M\u00fcller-Tidow","year":"2004","unstructured":"M\u00fcller-Tidow C, Steffen B, Cauvet T, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol. 2004;24:2890\u2013904.","journal-title":"Mol Cell Biol"},{"key":"2994_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/leu.2016.167","volume":"31","author":"S Weng","year":"2017","unstructured":"Weng S, Matsuura S, Mowery CT, et al. Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity. Leukemia. 2017;31:159\u201369.","journal-title":"Leukemia"},{"key":"2994_CR20","doi-asserted-by":"crossref","unstructured":"Vitkevi\u010dien\u0117 A, Skliut\u0117 G, \u017du\u010denka A, Borutinskait\u0117 V, Navakauskien\u0117 R. Potential Prognostic Markers for Relapsed\/Refractory vs. Responsive Acute Myeloid Leuk Cancers (Basel) 2022;14.","DOI":"10.3390\/cancers14112752"},{"key":"2994_CR21","doi-asserted-by":"publisher","first-page":"106194","DOI":"10.1016\/j.leukres.2019.106194","volume":"84","author":"S Yun","year":"2019","unstructured":"Yun S, Sharma R, Chan O, et al. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019;84:106194.","journal-title":"Leuk Res"},{"key":"2994_CR22","doi-asserted-by":"publisher","first-page":"115283","DOI":"10.1016\/j.bcp.2022.115283","volume":"205","author":"K Hege Hurrish","year":"2022","unstructured":"Hege Hurrish K, Qiao X, Li X, et al. Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia. Biochem Pharmacol. 2022;205:115283.","journal-title":"Biochem Pharmacol"},{"key":"2994_CR23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-20-1346","volume":"27","author":"HE Ramsey","year":"2021","unstructured":"Ramsey HE, Greenwood D, Zhang S, et al. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. Clin Cancer Res. 2021;27:598\u2013607.","journal-title":"Clin Cancer Res"},{"key":"2994_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","volume":"5","author":"DA Luedtke","year":"2020","unstructured":"Luedtke DA, Su Y, Ma J, et al. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduct Target Ther. 2020;5:17.","journal-title":"Signal Transduct Target Ther"},{"key":"2994_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1756-8722-7-2","volume":"7","author":"S L\u00fc","year":"2014","unstructured":"L\u00fc S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol. 2014;7:2.","journal-title":"J Hematol Oncol"},{"key":"2994_CR26","doi-asserted-by":"publisher","first-page":"692497","DOI":"10.3389\/fonc.2021.692497","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Ye J, Yang Y, et al. The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia. Front Oncol. 2021;11:692497.","journal-title":"Front Oncol"},{"key":"2994_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.21037\/atm-22-1459","volume":"10","author":"F Yuan","year":"2022","unstructured":"Yuan F, Li D, Li G, Cheng C, Wei X. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms. Ann Transl Med. 2022;10:490.","journal-title":"Ann Transl Med"},{"key":"2994_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"139","author":"CP Mill","year":"2022","unstructured":"Mill CP, Fiskus W, DiNardo CD, et al. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022;139:907\u201321.","journal-title":"Blood"},{"key":"2994_CR29","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1073\/pnas.1818539116","volume":"116","author":"XJ Chen","year":"2019","unstructured":"Chen XJ, Zhang WN, Chen B, et al. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-\u03baB repressing factor. Proc Natl Acad Sci U S A. 2019;116:2220\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2994_CR30","doi-asserted-by":"publisher","first-page":"111378","DOI":"10.1016\/j.biopha.2021.111378","volume":"137","author":"C Zhou","year":"2021","unstructured":"Zhou C, Li J, Du J, et al. HMGCS1 drives drug-resistance in acute myeloid leukemia through endoplasmic reticulum-UPR-mitochondria axis. Biomed Pharmacother. 2021;137:111378.","journal-title":"Biomed Pharmacother"},{"key":"2994_CR31","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488\u201393.","journal-title":"Nucleic Acids Res"},{"key":"2994_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"2994_CR33","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28:2529\u201337.","journal-title":"J Clin Oncol"},{"key":"2994_CR34","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1182\/blood-2010-03-270991","volume":"116","author":"HJ de Jonge","year":"2010","unstructured":"de Jonge HJ, Valk PJ, Veeger NJ, et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood. 2010;116:1747\u201354.","journal-title":"Blood"},{"key":"2994_CR35","first-page":"917","volume":"15","author":"G Yu","year":"2018","unstructured":"Yu G, Yin C, Jiang L, et al. Amyloid precursor protein has clinical and prognostic significance in AML1-ETO-positive acute myeloid leukemia. Oncol Lett. 2018;15:917\u201325.","journal-title":"Oncol Lett"},{"key":"2994_CR36","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1080\/10428194.2024.2400228","volume":"65","author":"Z Yin","year":"2024","unstructured":"Yin Z, Gao Y, Bu X, et al. Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis. Leuk Lymphoma. 2024;65:2138\u201350.","journal-title":"Leuk Lymphoma"},{"key":"2994_CR37","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138:1120\u201336.","journal-title":"Blood"},{"key":"2994_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","volume":"6","author":"R Zhu","year":"2021","unstructured":"Zhu R, Li L, Nguyen B, et al. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther. 2021;6:186.","journal-title":"Signal Transduct Target Ther"},{"key":"2994_CR39","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3324\/haematol.2018.211110","volume":"104","author":"VG Ramakrishnan","year":"2019","unstructured":"Ramakrishnan VG, Miller KC, Macon EP, et al. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. Haematologica. 2019;104:2061\u201374.","journal-title":"Haematologica"},{"key":"2994_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12094-012-0926-8","volume":"15","author":"MD Delgado","year":"2013","unstructured":"Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Le\u00f3n J. MYC oncogene in myeloid neoplasias. Clin Transl Oncol. 2013;15:87\u201394.","journal-title":"Clin Transl Oncol"},{"key":"2994_CR41","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ccr.2014.06.014","volume":"26","author":"Y Li","year":"2014","unstructured":"Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell. 2014;26:262\u201372.","journal-title":"Cancer Cell"},{"key":"2994_CR42","doi-asserted-by":"crossref","unstructured":"Wood CD, Veenstra H, Khasnis S, et al. MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. Elife. 2016;5:e18270.","DOI":"10.7554\/eLife.18270"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02994-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02994-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02994-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:17:54Z","timestamp":1787019474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02994-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02994-x","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in compliance with Declaration of Helsinki principles. All procedures were approved by the ethics committee review board of each participating hospital.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"446"}}